Encelimab Biosimilar – Anti-LAG3, CD223 mAb – Research Grade

Introduction

Encelimab Biosimilar, also known as Anti-LAG3 or CD223 monoclonal antibody, is a research grade therapeutic antibody that targets the Lymphocyte Activation Gene 3 (LAG3) protein. LAG3 is a cell surface molecule that is primarily expressed on immune cells and plays a critical role in regulating immune responses. Encelimab Biosimilar is a promising new treatment option for various autoimmune diseases and cancers, and its unique structure and mechanism of action make it a highly sought-after therapeutic target.

Structure of Encelimab Biosimilar

Encelimab Biosimilar is a monoclonal antibody, meaning it is a laboratory-produced protein that is designed to mimic the function of natural antibodies in the body. It is composed of two heavy chains and two light chains, which are held together by disulfide bonds. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the end of each arm and a crystallizable fragment (Fc) at the base.

The Fab regions of Encelimab Biosimilar are responsible for binding to the LAG3 protein, while the Fc region is responsible for activating immune cells and promoting antibody-mediated cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This dual mechanism of action makes Encelimab Biosimilar a potent therapeutic agent for targeting LAG3.

Activity of Encelimab Biosimilar

Encelimab Biosimilar works by binding to the LAG3 protein on the surface of immune cells, including T cells, B cells, and natural killer (NK) cells. This binding prevents LAG3 from interacting with its natural ligands, such as major histocompatibility complex (MHC) class II molecules, which are essential for immune cell activation and function.

By blocking the interaction between LAG3 and its ligands, Encelimab Biosimilar helps to restore proper immune function and balance. It can also enhance the activity of other immune cells, such as T cells and NK cells, by promoting their activation and proliferation. In addition, the Fc region of Encelimab Biosimilar can trigger the destruction of LAG3-expressing cells through ADCC and ADCP, further contributing to its therapeutic activity.

Applications of Encelimab Biosimilar

Encelimab Biosimilar is currently being investigated for its potential in treating various autoimmune diseases and cancers. In autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, LAG3 is overexpressed and plays a role in suppressing immune responses. By targeting LAG3, Encelimab Biosimilar can help to restore immune balance and alleviate disease symptoms.

In cancer, LAG3 is often expressed on tumor-infiltrating immune cells, which can suppress anti-tumor immune responses. By blocking LAG3, Encelimab Biosimilar can enhance the activity of immune cells against cancer cells and potentially improve the efficacy of other cancer treatments, such as chemotherapy and immunotherapy.

Conclusion

Encelimab Biosimilar, also known as Anti-LAG3 or CD223 monoclonal antibody, is a promising new therapeutic agent that targets the LAG3 protein. Its unique structure and mechanism of action make it a potent therapeutic target for various autoimmune diseases and cancers. Ongoing research and clinical trials will further elucidate the full potential of Encelimab Biosimilar in treating these diseases and improving patient outcomes.